shutterstock_1106850689_piotr_swat

Piotr Swat / Shutterstock.com

19 May 2022Sarah Speight

NIH COVID-19 deal broadens access for poorer nations

The Medicines Patent Pool (MPP) and World Health Organization’s (WHO) COVID-19 Technology Access Pool (C-TAP) have signed a deal aiming to open up new technologies to people living in poorer countries.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Kite Pharma enters into licensing agreement with NIH

9 June 2014 Kite Pharma, a biotech company, has entered into a licensing agreement with the US’s National Institute of Health that will give it the IP rights to T-cell therapies developed to treat cancer.

NIH chooses not to use ‘march-in rights’ in prostate drug row

21 June 2016 The US National Institutes of Health has decided not to exercise its “march in-rights” for the Xtandi prostate drug, which is marketed by Astellas Pharma, despite calls from politicians to license the drug in a bid to lower its price.

More on this story

Biotechnology

Kite Pharma enters into licensing agreement with NIH

9 June 2014 Kite Pharma, a biotech company, has entered into a licensing agreement with the US’s National Institute of Health that will give it the IP rights to T-cell therapies developed to treat cancer.

NIH chooses not to use ‘march-in rights’ in prostate drug row

21 June 2016 The US National Institutes of Health has decided not to exercise its “march in-rights” for the Xtandi prostate drug, which is marketed by Astellas Pharma, despite calls from politicians to license the drug in a bid to lower its price.

More on this story

Biotechnology

Kite Pharma enters into licensing agreement with NIH

9 June 2014 Kite Pharma, a biotech company, has entered into a licensing agreement with the US’s National Institute of Health that will give it the IP rights to T-cell therapies developed to treat cancer.

NIH chooses not to use ‘march-in rights’ in prostate drug row

21 June 2016 The US National Institutes of Health has decided not to exercise its “march in-rights” for the Xtandi prostate drug, which is marketed by Astellas Pharma, despite calls from politicians to license the drug in a bid to lower its price.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent